The Claim
In adults with type 2 diabetes and chronic kidney disease who are already receiving ACE inhibitor or ARB therapy, weekly subcutaneous administration of semaglutide at a dose of 1.0 mg reduces the risk of all-cause mortality by 20% compared to placebo over a median follow-up period of 3.4 years.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
If you're an adult with type 2 diabetes and kidney problems and you're already on certain blood pressure meds, taking a weekly semaglutide shot might lower your chance of dying from any cause by 20% over about 3 years.
See the scientific wording
In adults with type 2 diabetes and chronic kidney disease on ACE inhibitor or ARB therapy, weekly subcutaneous semaglutide at 1.0 mg reduces the risk of death from any cause by 20% compared to placebo over a median of 3.4 years.
What the research says
1 studyStudy: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
The study gave a weekly semaglutide shot to people with type 2 diabetes and kidney disease and found they were 20% less likely to die from any cause, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.